This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.

开始日期2025-12-31

申办/合作机构

Sarcoma Alliance for Research through Collaboration

CTR20253602

/ Recruiting临床2期

评价注射用西罗莫司（白蛋白结合型）联合奥曲肽长效注射液在转移性胃肠胰神经内分泌瘤（GEP-NETs）患者中安全性和有效性的II/III期研究

II期主要目的：评价注射用西罗莫司（白蛋白结合型）联合奥曲肽长效注射液在转移性GEP-NETs患者中的安全性、有效性，确定RP3D；次要目的：评价注射用西罗莫司（白蛋白结合型）联合奥曲肽长效注射液在转移性GEP-NETs患者的初步抗肿瘤活性、PK特征、生物标志物与疗效的相关性。 III期主要目的：评价注射用西罗莫司（白蛋白结合型）联合奥曲肽长效注射液对比依维莫司在转移性GEP-NETs患者中的有效性；次要目的：评价注射用西罗莫司（白蛋白结合型）联合奥曲肽长效注射液对比依维莫司在转移性GEP-NETs患者中的安全性、PK特征、生物标志物与疗效的相关性。

开始日期2025-09-15

申办/合作机构

石药集团中奇制药技术（石家庄）有限公司

NCT06941142

/ Not yet recruiting临床1期

An Ib/III Study to Evaluate the Safety and Efficacy of Sirolimus（Albumin-bound）in Combination With Palbociclib and Fulvestrant in Patients With Advanced HR- Positive, HER2- Negative Breast Cancer

This study adopts multicenter/randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population.

开始日期2025-04-30

申办/合作机构

石药集团中奇制药技术（天津）有限公司

100 项与西罗莫司(白蛋白结合型) 相关的临床结果

登录后查看更多信息

100 项与西罗莫司(白蛋白结合型) 相关的转化医学

登录后查看更多信息

100 项与西罗莫司(白蛋白结合型) 相关的专利（医药）

登录后查看更多信息

13,495

项与西罗莫司(白蛋白结合型) 相关的文献（医药）

2025-12-01·INFLAMMATION RESEARCH

Silencing aquaporin 1 inhibits autophagy to exert anti-rheumatoid arthritis effects in TNF-α-induced fibroblast-like synoviocytes and adjuvant-induced arthritis rats

Article

作者: Li, Rong ; Lv, Min ; Zhang, Man-Yu ; Huang, Yan ; Li, Ling-Ling ; Xu, Ze-Shan ; Cai, Li ; Gu, Sheng-Long ; Wang, Meng-Qing ; Zhou, Meng-Yuan

OBJECTIVE:

Fibroblast-like synoviocytes (FLS) are key players in rheumatoid arthritis (RA) by resisting apoptosis via increased autophagy. Elevated synovial aquaporin 1 (AQP1) affects RA FLS behaviors, but its relationship with FLS autophagy is unclear. We aim to clarify that silencing AQP1 inhibits autophagy to exert its anti-RA effects.

METHODS:

We studied the effects and mechanisms of AQP1 silencing on autophagy in TNF-α-induced RA FLS and examined the crucial role of autophagy inhibition in its impacts on RA FLS pathogenic behaviors. We explored whether silencing synovial AQP1 relieved rat adjuvant-induced arthritis (AIA) by reducing synovial autophagy.

RESULTS:

TNF-α stimulation increased AQP1 expression and autophagy levels in RA FLS, with a positive correlation between them. AQP1 silencing inhibited autophagy in TNF-α-stimulated RA FLS, along with suppressing proliferation, promoting apoptosis, and mitigating inflammation. Notably, the inhibitory effects of AQP1 silencing on RA FLS pathogenic behaviors were cancelled by autophagy activation with rapamycin (Rapa) but enhanced by autophagy inhibition using 3-Methyladenine. Mechanistically, silencing AQP1 enhanced the binding of Bcl-2 to Beclin1 by decreasing Beclin1-K63 ubiquitination, thus inhibiting RA FLS autophagy. In vivo, silencing synovial AQP1 relieved the severity and development of rat AIA, alongside reducing Ki67 expression, promoting apoptosis, and decreasing autophagy within AIA rat synovium. Expectedly, the Rapa co-administration nullified the anti-AIA effects of silencing synovial AQP1.

CONCLUSION:

These findings reveal that silencing AQP1 inhibits RA FLS pathogenic behaviors and attenuates rat AIA through autophagy inhibition. This study may help clarify the pathogenic role of AQP1 in enhancing autophagy during RA development.

2025-12-01·Biomaterials advances

An early rapamycin-releasing nerve wrap with dual function for nerve regeneration and adhesion prevention

Article

作者: Zeng, Qi ; Xu, Wu ; Shi, Xudong ; Li, Ruijun ; Zhao, Yuanyuan ; Kang, Shiqi ; Wang, Naiyu

Limited ability of nerve regeneration and the formation of nerve adhesions result to poor outcomes of peripheral nerve injury (PNI) following surgical nerve repair. Currently, there is no efficient therapy for the improvement of functional recovery after surgical repair. Rapamycin (Rapa) has been found useful for promoting nerve regeneration through removing cellular debris at the early stages after PNI. However, its lower oral bioavailability and significant adverse effects limit its clinical application. In this study, we developed a biocompatible nerve wrap based on biocompatible monomethoxy poly (ethylene glycol)-poly (lactic-co-glycolic acid) (mPEG-PLGA) for the local delivery of Rapa. The Rapa-mPEG-PLGA nerve wrap exhibited a rough surface and good hydrophilicity with strong mechanical strength. In vitro release studies revealed an initial rapid phase within the first 8 days, followed by a stable release about 10 days. The released Rapa remained its bioactivity to induce autophagy and promote cell migration. In a rat model of sciatic nerve transection and immediate repair, the implantation of Rapa-mPEG-PLGA nerve wrap significantly enhanced axonal regeneration and myelination. Furthermore, the nerve wraps effectively prevented the occurrence of nerve adhesions. Improved functional recovery was observed with Rapa-mPEG-PLGA membrane wrap post-surgery 4 weeks and 8 weeks. In summary, the Rapa-loaded mPEG-PLGA nerve wrap promoted nerve regeneration by releasing Rapa at the early stage after injury, and acted as a physical barrier to reduce nerve adhesions. This local dual-action strategy is a promising candidate for clinical translation in the treatment of PNI following surgical repair.

2025-12-01·REPRODUCTIVE TOXICOLOGY

Blocking T-type calcium channels disrupts spermatogenesis in vivo and adversely affects spermatocytes in vitro by impairing mitochondrial function and autophagic flux

Article

作者: Nie, Junyu ; Huang, Shiqin ; Chen, Hao ; Wang, Xiaorong ; Wang, Lei ; Pu, Liping ; Zhao, Xiuling ; Liu, Lin

T-type calcium channels are pivotal in spermatogenesis. To evaluate the molecular mechanisms by which T-type calcium channels regulate spermatogenesis, we constructed animal and cellular models using T-type calcium channel inhibitor flunarizine (FNZ). Intraperitoneal administration of FNZ (30 mg/kg) significantly impaired sperm motility, inhibited testicular germ cell proliferation, and disrupted sperm mitochondrial function in male mice. FNZ, at concentrations of 7.5 μM, 15 μM, and 30 μM, significantly inhibited mouse spermatocyte (GC-2) cells proliferation. The detrimental effects of FNZ were mediated through the disruption of calcium homeostasis, mitochondrial dysfunction, and the induction of apoptosis. Moreover, FNZ exposure resulted in the accumulation of autophagosomes and an upregulation of P62 protein, which is implicated in autophagic degradation. Notably, the autophagy activator Rapamycin (Rapa) was found to mitigate FNZ-induced cellular damage in GC-2 cells by enhancing autophagy process. Conversely, chloroquine (CQ), an autophagy inhibitor that disrupts lysosomal degradation, corroborated the role of FNZ in autophagy modulation. Our results indicate that FNZ induces mitochondrial damage, impairs sperm motility and spermatocyte proliferation, and is accompanied by obstacles to autophagic flux.

123

项与西罗莫司(白蛋白结合型) 相关的新闻（医药）

2025-10-15

·米内网

【瞩目】石药1类新药大爆发，1款报产、5款获批临床

精彩内容近日，石药集团1类新药喜讯频传：依达格鲁肽α注射液申报NDA获受理，拟用于超重或肥胖等体重管理；SYS6010、SYS6043、DP303c注射液、SYS6002和注射用JSKN003获批IND，均拟用于治疗实体瘤。米内网数据显示，消化系统及代谢生物药、抗肿瘤和免疫调节剂生物药2025H1在中国三大终端六大市场销售额分别超190亿元和570亿元。石药集团部分1类新药审评进度来源：CDE官网，米内网整理依达格鲁肽α注射液是一款重组人源胰高血糖素样肽-1(hGLP-1)Fc融合蛋白注射液，可在控制饮食和增加运动的基础上，用于超重或肥胖成人的长期体重管理，目前该适应症已申报上市获受理。此外，该新药拟用于2型糖尿病的两项Ⅲ期临床试验正积极推进中。 SYS6010（EGFR ADC）、SYS6043（B7-H3 ADC）、DP303c注射液（HER2 ADC）和SYS600（ROR1 ADC）均可用于联合注射用西罗莫司（白蛋白结合型）治疗晚期实体瘤，注射用JSKN003（HER2双抗ADC）可单药或联合注射用多西他赛（白蛋白结合型）或联合其他用于乳腺癌新辅助治疗。5款新药均于近日获得临床试验默示许可。在中国三大终端六大市场（统计范围详见本文末），消化系统及代谢生物药、抗肿瘤和免疫调节剂生物药2024年销售额分别在350亿元和1000亿元以上，2025H1各以8.67%和12.77%的增速增长至超190亿元和570亿元。消化系统及代谢生物药、抗肿瘤和免疫调节剂生物药销售趋势（单位：万元）来源：米内网格局数据库近年来，石药集团持续加大研发投入，不断加快创新转型步伐。其中1类创新药方面（不含预防用生物药，下同），2025年至今，集团已有2款新药申报上市，分别为安尼妥单抗注射液、依达格鲁肽α注射液；24款新品获批临床，涉及全身用抗感染药物、神经系统药物、抗肿瘤和免疫调节剂等多个治疗大类。石药集团今年以来获批临床的1类新药来源：米内网中国申报进度（MED）数据库 24款获批临床的新药中，从最高研发进度看，SYS6010（非小细胞肺癌）、注射用JSKN003（乳腺癌、卵巢癌）、SYHX1901片（银屑病）、重组人源化抗HER2双特异性抗体注射液（乳腺癌）、重组人源化抗表皮生长因子受体单抗注射液（结直肠癌、非小细胞肺癌）等已步入Ⅲ期临床，SYHA1813口服液（小细胞肺癌）正处Ⅱ/Ⅲ期临床阶段。资料来源：米内网数据库、CDE官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至10月15日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

抗体药物偶联物申请上市临床3期临床申请免疫疗法

2025-10-08

·ioncology

ESMO 2025丨一文汇总乳腺癌领域中国专家入选的壁报研究

点击蓝字，关注我们编者按：2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林召开，作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学专家参与，为全球学者提供了良好的交流平台。日前，ESMO已公布大会常规摘要（含Oral、Mini Oral、Poster三类）和“突破性摘要”（Late-Breaking Abstract，LBA）标题。肿瘤瞭望特将目前乳腺癌领域入选的中国专家投稿壁报研究进行汇总，并诚邀您持续关注重磅研究进展！ Breast cancer, early stage （早期乳腺癌） 298P - Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in Asian population with HER2-positive breast cancer 用于预测亚洲HER2阳性乳腺癌患者复发和生存风险的新型HER2RI检测方法的开发和验证讲者：Yi-Kun Kang (Beijing, China) 300P - TIME-HER: A Dynamic Predictive Model for Prognosis of HER2-Positive Early Breast Cancer after HER2-targeted Therapy TIME-HER：HER2靶向治疗后HER2阳性早期乳腺癌预后的动态预测模型讲者：Qingyao Shang (Beijing, China) 305P - Neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer: three-year outcomes from the MUKDEN 01 study MUKDEN 01研究三年随访结果：吡咯替尼联合来曲唑及达尔西利新辅助治疗三阳性乳腺癌的疗效分析讲者：刘彩刚（中国医学大学附属盛京医院） 306P - Neoadjuvant SHR-A1811 with or without pyrotinib in HER2-positive breast cancer (MUKDEN 07): A multi-cohort, multicenter, phase II clinical trial MUKDEN 07研究：一项针对HER2阳性乳腺癌的多队列、多中心Ⅱ期临床试验，评估新辅助治疗中SHR-A1811联合或不联合吡咯替尼的疗效讲者：刘彩刚（中国医学大学附属盛京医院） 312P - Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c, lymph node-negative, and hormone receptor-negative breast cancer: a study based on the SEER database and a Chinese cohort T1c期、淋巴结阴性且激素受体阴性乳腺癌患者新辅助治疗与辅助治疗生存结局的对比研究：基于SEER数据库与中国队列的分析讲者：Shiyu Liang (Chengdu, China) 317P - Myeloprotection with Trilaciclib in Hormone Receptor (HR)-Negative early breast cancer receiving adjuvant therapy Trilaciclib在激素受体（HR）阴性早期乳腺癌辅助治疗中的骨髓保护作用讲者：Jiajia Huang (Guangzhou, China) 344P - Inadequate ovarian suppression in young premenopausal women with estrogen receptor-positive breast cancer on ovarian suppression therapy 接受卵巢功能抑制治疗的年轻绝经前雌激素受体阳性乳腺癌患者卵巢抑制不充分的现象讲者：Dar-Ren Chen (Changhua City, Taiwan) 348P - Ten-Year Outcomes of Epirubicin Plus Paclitaxel Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel in Hormone Receptor–Positive, ERBB2-Negative, Node-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial 表柔比星联合紫杉醇对比表柔比星联合环磷酰胺序贯紫杉醇治疗激素受体阳性、ERBB2阴性、淋巴结阳性乳腺癌的10年随访结局比较：一项3期随机临床试验讲者：Liuliu Quan (Beijing, China) 382P - A modern DCIS-IBC guide board for postoperative upgrading in ductal carcinoma in situ 导管原位癌术后升级为浸润性乳腺癌的现代风险评估指南框架讲者：Chenglong Duan (xian, China) 383P - Spatial transcriptomics reveals biological disparities in ipsilateral breast tumor recurrence after breast-conserving surgery 空间转录组学揭示保乳术后同侧乳腺肿瘤复发的生物学差异讲者：FEILIN QU (Shanghai, China) 385P - Is axillary intervention necessary for selected patients with cN0-1 breast cancer after neoadjuvant chemotherapy? 新辅助化疗后的cN0-1乳腺癌患者是否有必要进行腋窝干预？讲者：Yuhan Zhang (Xi'an, Shaanxi Province, China) 386P - The Innovative Lancet Technique for Breast-Conserving Oncoplastic Surgery in Small- to Medium-Sized Breasts with Tumors in the Lower Inner Quadrant: A Multicenter Retrospective Study (IOS Study) 针对中小乳房下内侧象限肿瘤的保乳整形手术创新Lancet技术：一项多中心回顾性研究（IOS研究）讲者：Wenjie Shi (Magdeburg, Germany) 389P - A Competing Risk Analysis Model to Explore the Impact of Postoperative Radiotherapy for Sentinel Lymph Node Micrometastases or ITCs in Female Breast Cancer 竞争风险分析模型探讨术后放疗对女性乳腺癌前哨淋巴结微转移或孤立肿瘤细胞（ITCs）的影响讲者：Yudong Zhou (xian, China) 391P - Application of Preoperative 3-dimensional Vascular Reconstruction Assessment in Preventing Ischemic Complications After Nipple-Sparing Mastectomy: A Randomized Controlled Trial 术前三维血管重建评估在预防保留乳头乳房切除术后缺血性并发症中的应用：一项随机对照试验讲者：Xiaoqi Zhang (Guangzhou, China) 398P - Patient-reported outcomes (PROs) with GnRHa as ovarian function suppression (OFS) treatment in pre-menopausal Chinese patients with hormone receptor-positive (HR+) early breast cancer (EBC): a real-world observational investigation GnRHa作为卵巢功能抑制（OFS）治疗绝经前激素受体阳性（HR+）早期乳腺癌（EBC）患者的患者报告结局（PROs）：一项真实世界观察性研究讲者：范蕾（复旦大学附属肿瘤医院） 403P - Axillary Lymph Node Dissection Offers No Survival Benefit in Breast Cancer Patients with Sentinel Lymph Node Micrometastases After Neoadjuvant Therapy 腋窝淋巴结清扫术对新辅助治疗后前哨淋巴结微转移的乳腺癌患者无生存获益讲者：Jianing Zhang (Xi'an, China) 414P - Prognostic Value of ER reduction rate between pre- and post- Neoadjuvant Chemotherapy in Patients with ER-Positive/HER2-Negative Breast Cancer 新辅助化疗前后ER降低率对ER阳性/ her2阴性乳腺癌患者的预后价值讲者：Shunyi Liu (Fuzhou, China) 416P - Diverse adjuvant treatment in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy: A single center real-world study 新辅助化疗后残留病灶的三阴性乳腺癌患者的多样化辅助治疗：一项单中心真实世界研究讲者：Xi Chen (Beijing, China) 417P - Proteomic analysis of residual disease identifies potential prognostic biomarkers of triple-negative breast cancer after neoadjuvant chemotherapy 三阴性乳腺癌新辅助化疗后残留病灶的蛋白质组学分析确定潜在的预后生物标志物讲者：Xi Chen (Beijing, China) 418P - Impact of BRCAness Status on Prognosis and Chemotherapy Sensitivity in Non-pCR Triple-Negative Breast Cancer Patients After Neoadjuvant Treatment BRCA样状态对新辅助治疗后未达病理完全缓解（non-pCR）三阴性乳腺癌患者预后及化疗敏感性的影响讲者：Hangcheng Xu (Beijing, China) Breast cancer, locally advanced （局部晚期乳腺癌） 466P - Efficacy and Safety of JS105, a Selective Inhibitor of Mutant PI3Kα, in Patients with Advanced Cancer 选择性突变型PI3Kα抑制剂JS105在晚期癌症患者中的疗效与安全性研究讲者：闫敏（河南省肿瘤医院） 468P - The Clinical Significance and Prognostic Impact of stromal tumor infiltrating lymphocytes in HER2-Positive Breast Cancer: Including a Neoadjuvant Subgroup Analysis HER2阳性乳腺癌间质肿瘤浸润淋巴细胞的临床意义和预后影响：包括新辅助治疗亚组分析讲者：Yujing Chang (Chengdu, China) 470P - Neoadjuvant cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) plus chemotherapy in early or locally advanced triple-negative breast cancer: supplementary biomarker analyses from CABIN trial 新辅助cadonilimab（抗pd -1/CTLA-4双特异性抗体）联合化疗治疗早期或局部晚期三阴性乳腺癌：来自CABIN试验的补充生物标志物分析讲者：TAO WU (Changde City, China) 472P - The mechanism and preclinical translational research of targeted inhibition of ATM enhancing the therapeutic efficacy of PD-1/PD-L1 inhibitors in triple-negative breast cancer by modulating CD8⁺T cells in the tumor immune microenvironment 靶向抑制ATM通过调控肿瘤免疫微环境中CD8⁺T细胞增强PD-1/PD-L1抑制剂治疗三阴性乳腺癌的机制及临床前转化研究讲者：Xiaojing Guo (Tianjin, China) 473P - Neoadjuvant Trilaciclib plus chemotherapy and anti-PD1-antibody for locally advanced triple-negative breast cancer: Preliminary short-term efficacy and safety results from a single-arm, multicenter, phase II trial 新辅助治疗中Trilaciclib联合化疗及抗PD-1抗体治疗局部晚期三阴性乳腺癌：一项单臂、多中心Ⅱ期试验的初步短期疗效与安全性结果讲者：Jiaxuan Liu (Beijing, China) 479P - H4K8la/CXCL10-driven M2 polarization via tumor cell-macrophage lactate feedback loop mediates doxorubicin resistance in TNBC H4K8la/CXCL10通过肿瘤细胞-巨噬细胞乳酸反馈回路驱动M2型巨噬细胞极化，介导三阴性乳腺癌对多柔比星的耐药性讲者：Qingqing Wang (Wuhan, China) Breast cancer, metastatic （转移性乳腺癌） 490P - Bireociclib plus Letrozole/Anastrozole versus Placebo plus Letrozole/Anastrozole for the Treatment of HR+/HER2- Advanced Breast Cancer: Interim Analysis of BRIGHT-3 study 吡洛西利联合来曲唑/阿那曲唑vs安慰剂联合来曲唑/阿那曲唑治疗HR+/HER2-晚期乳腺癌的比较：BRIGHT-3研究的期中分析讲者：张清媛（哈尔滨医科大学附属肿瘤医院） 495P - Safety and efficacy of nab-Sirolimus (HB1901) + endocrine therapy in HR+/HER2- advanced breast cancer after standard therapy failure: A multicenter, open-label, phase 2 study 白蛋白结合型西罗莫司（HB1901）联合内分泌治疗在标准治疗失败后的HR+/HER2-晚期乳腺癌中的安全性和有效性：一项多中心、开放标签、II期研究讲者：马飞（中国医学科学院肿瘤医院） 501P - Efficacy and Safety Outcomes across Young to Older Age Groups of Patients with HR+/HER2- Advanced Breast Cancer Treated with Bireociclib plus Endocrine Therapy: a Pooled Analysis of BRIGHT Studies 吡洛西利联合内分泌治疗HR+/HER2-晚期乳腺癌年轻和老年患者的疗效和安全性结局：BRIGHT研究的汇总分析讲者：张清媛（哈尔滨医科大学附属肿瘤医院） 505P - Safety and Preliminary Efficacy of a Novel CDK2/4 Inhibitor TYK-00540 in Patients with Advanced Solid Tumors: Results from a Phase I Dose-Escalation Study 新型CDK2/4抑制剂TYK-00540用于晚期实体瘤患者的安全性和初步疗效：来自1期剂量递增研究的结果讲者：孟艳春（复旦大学附属肿瘤医院） 509P - A Phase II Trial of Anlotinib and Fulvestrant in Patients with HR-Positive and HER2-Negative, Secondary Hormone Resistant, Metastatic Breast Cancer 安罗替尼+氟维司群治疗HR+/HER2-继发性激素抵抗性转移性乳腺癌患者的2期试验讲者：王晓稼（浙江省肿瘤医院） 513P - TY-302，a CDK4/6 inhibitor (CDK4/6i), combined with toremifene in patients with advanced solid tumors: Results from a phase Ia/Ib study. CDK4/6抑制剂（CDK4/6i）TY-302联合托瑞米芬治疗晚期实体瘤：Ia/Ib期研究结果讲者：马飞（中国医学科学院肿瘤医院） 518P - Efficacy and Safety of Treatments in HR+HER2- Advanced Breast Cancer After Cyclin-Dependent Kinase 4/6 inhibitors progression: A Network Meta-Analysis and Scoping Review CDK4/6抑制剂治疗进展后HR+/HER2-晚期乳腺癌治疗的疗效和安全性：一项网状meta分析和范围综述讲者：佟仲生（天津医科大学肿瘤医院） 525P - Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials CDK4/6抑制剂后治疗方案对HR+/HER2阴-晚期乳腺癌的疗效和安全性：一项随机对照试验的网络荟萃分析讲者：Junxiao Wang (Fuzhou, China) 529P - PIK3CA Mutation Profiles in Primary and Metastatic Lesions in Chinese Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer 中国激素受体阳性、HER2阴性乳腺癌患者原发性和转移性病灶中PIK3CA的突变谱讲者：徐贵颖（吉林省肿瘤医院） 538P - Preliminary efficacy and safety of TQB2102 in patients with HER2 positive Recurrent/Metastatic Breast Cancer: Results from a phase Ib study TQB2102治疗HER2阳性复发/转移性乳腺癌患者的初步疗效和安全性：一项Ib期研究的结果讲者：张清媛（哈尔滨医科大学附属肿瘤医院） 545P - A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined with Chemotherapy (IPyC) for HER2+ Metastatic Breast Cancer 伊尼妥单抗+吡咯替尼联合化疗（IPyC）治疗HER2+转移性乳腺癌的疗效和安全性回顾性多中心队列研究讲者：Wu Fan (Fuzhou, China) 546P - Efficacy and safety of Pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer: a multicenter, retrospective, real-world study 既往曲妥珠单抗和帕妥珠单抗治疗HER2阳性转移性乳腺癌后，接受以吡咯替尼为基础的治疗的有效性和安全性：一项多中心、回顾性、真实世界研究讲者：王涛（解放军总医院第五医学中心） 549P - Phase I study of ARX788 plus toripalimab in advanced solid tumors with expansion in HER2-low advanced breast cancer. ARX788联合特瑞普利单抗治疗HER2低表达的晚期实体瘤的I期研究讲者：王晓稼（浙江省肿瘤医院） 551P - SHR-A1811 combined with Adebrelimab in HR-/HR-low, HER2-low metastatic breast cancer: Preliminary results from an open-label, single-arm, phase II Trial SHR-A1811联合阿得贝利单抗治疗HR-/HR低表达、HER2低表达的转移性乳腺癌：开放标签、单臂、II期试验的初步结果讲者：Jiaxuan Liu (Beijing, China) 552P - Phase I study data of a novel eribulin-based HER2 ADC: Safety and efficacy of SMP-656 in HER2-expressing solid tumor 基于艾立布林的新型HER2 ADC的 I期研究数据：SMP-656在HER2表达实体瘤中的安全性和疗效讲者：张剑（复旦大学附属肿瘤医院） 556P - Updated Efficacy of Anti-TROP2 ADC ESG401 for First-Line Metastatic TNBC 抗TROP2 ADC ESG401治疗一线转移性TNBC的最新疗效讲者：邱福铭（浙江大学医学院附属第二医院） 559P - SHR-A1921, a novel trophoblast cell-surface antigen 2 targeted antibody-drug conjugate, with or without adebrelimab in advanced triple-negative breast cancer (TNBC): data from two open-label, multicenter clinical trials SHR-A1921，一种新型靶向滋养层细胞表面抗原2的抗体药物偶联物，联合或不联合阿得贝利单抗（adebrelimab）治疗晚期三阴性乳腺癌（TNBC）：两项开放标签、多中心临床试验的数据讲者：史业辉（天津医科大学肿瘤医院） 564P - Combined PD-1 Inhibition and Chidamide in Metastatic Triple-Negative Breast Cancer: A Phase II Clinical Trial PD-1抑制联合西达本胺治疗转移性三阴性乳腺癌：一项II期临床试验讲者：Sifen Wang (Guangzhou, China) 571P - Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study 阿得贝利单抗联合阿帕替尼和依托泊苷治疗HER2阴性乳腺癌脑转移：一项II期研究讲者：王涛（解放军总医院第五医学中心） 581P - Improving Survival in Heavily Treated Metastatic Breast Cancer Through Personalized Chemotherapy Selection Using Ex Vivo Expanded Circulating Tumor Cells 通过使用体外扩增的循环肿瘤细胞进行个体化化疗选择来改善重度治疗的转移性乳腺癌患者的生存讲者：Wen-Ying Lin (Taipei City, Taiwan) 595P - Efficacy and Safety of Rivaroxaban Prophylaxis on Catheter-Related Thrombosis in Breast Cancer Patients Undergoing Chemotherapy with PICC: A Prospective Cohort Study 利伐沙班预防乳腺癌化疗患者PICC导管相关性血栓形成的有效性和安全性：一项前瞻性队列研究讲者：Die Sang (Beijing, China) 598P - An observational clinical study to evaluate the consistency of PIK3CA mutations in tumor tissues and corresponding plasma circulating tumor DNA (ctDNA) of patients with HR+ mBC 一项观察性临床研究，旨在评估HR+mBC患者肿瘤组织中PIK3CA突变和相应血浆循环肿瘤DNA（ctDNA）的一致性讲者：欧阳取长（湖南省肿瘤医院） 599P - Efficacy and Safety of Dalpiciclib Combined with Endocrine Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer 在既往CDK4/6抑制剂经治的HR+/HER2-晚期乳腺癌发生进展后，达尔西利联合内分泌治疗的疗效和安全性讲者：李俏（中国医学科学院肿瘤医院） 600P - Matching-Adjusted Indirect Comparison of Bireociclib Plus Fulvestrant versus Dalpiciclib Plus Fulvestrant as Second-Line Treatment of HR+/HER2- Advanced Breast Cancer (ABC) 通过匹配校正间接比较吡洛西利+氟维司群与达尔西利+氟维司群作为HR+/HER2-晚期乳腺癌二线治疗的疗效（ABC）讲者：王佳玉（中国医学科学院肿瘤医院） 602P - VMP1 inhibits the progression of breast cancer via regulating PI3K/AKT and MEK/ ERK signaling pathway VMP1通过调控PI3K/AKT和MEK/ ERK信号通路抑制乳腺癌的进展讲者：Shuzhao Chen (Guangzhou, China) 609P - Real-world Application of 18F-FES PET/CT on HR+ Breast Cancer Patients with Brain Metastases 18F-FES PET/CT在HR+乳腺癌脑转移患者中的实际应用讲者：王碧芸（复旦大学附属肿瘤医院） 612P - Impact of Rivaroxaban on Prophylaxis Against Catheter-Related Thrombosis in Breast Cancer Patients: A cohort study 利伐沙班对预防乳腺癌患者导管相关血栓形成的影响：一项队列研究讲者：Yurong Zhang (Beijing, China) 625TiP - A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer Trop-2 ADC联合治疗晚期三阴性乳腺癌的多中心、前瞻性、队列研究讲者：郝春芳（天津医科大学肿瘤医院） 631eP - Real-world study on the efficacy and safety of Dalpiciclib in elderly patients with HR-positive, HER2-negative advanced breast cancer in the Xinjiang region 新疆地区老年HR+/HER2-晚期乳腺癌患者应用达尔西利疗效及安全性的真实世界研究讲者：Yan Li (Urumqi, China) 635eP - The necessity of adding anti-HER2 antibody to TKI in trastuzumab-resistant, HER2-positive ABC: a multicenter real-world study 曲妥珠单抗耐药的HER2阳性ABC患者中，TKI联合抗HER2抗体的必要性：一项多中心真实世界研究讲者：Ruixia Song (Beijing, China) 636eP - Real-world efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer: Evidence from a Chinese population T-DXd在HER2阳性和HER2低表达转移性乳腺癌中的真实疗效和安全性：来自中国人群的证据讲者：张剑（复旦大学附属肿瘤医院） 637eP - Clinical Outcomes and Safety of Sacituzumab Govetican in Chinese Metastatic HER2 Negative Breast Cancer Patients: A Real World Study SG治疗中国转移性HER2阴性乳腺癌患者的临床结局和安全性：一项真实世界研究讲者：Yuxin Mu (Shanghai, China) 638eP - Construction of an Efficacy Prediction Model for T-DXd Treatment of HER2-Positive and HER2-Negative Breast Cancer Based on Hematological Indicators: A Multicenter Real-World Study 基于血液学指标构建T-DXd治疗HER2阳性和HER2阴性乳腺癌疗效预测模型：一项多中心真实世界研究讲者：Yanfang Su (Beijing, China) 647eP - Efficacy and safety profiles of PARP inhibitors in Chinese patients with metastatic breast cancer: a multi-center real-world study PARP抑制剂治疗中国转移性乳腺癌患者的疗效和安全性：一项多中心真实世界研究讲者：Xuenan Peng (Beijing, China) 648eP - Analysis of efficacy and safety of eribulin in the treatment of advanced breast cancer in the real-world 艾立布林治疗晚期乳腺癌的真实世界疗效和安全性分析讲者：Xiao Chen (Shenzhen, China) 652eTiP - A Phase 1b/2 study of FWD1802, a novel oral estrogen receptor (ER) degrader (SERD), in combination with multiple CDK4/6 inhibitors (CDK4/6i) and mTOR inhibitor in ER+/HER2- advanced or metastatic breast cancer (a/m BC) FWD1802（一种新型口服ER降解剂）联合多种CDK4/6抑制剂（CDK4/6i）和mTOR抑制剂治疗ER+/HER2-晚期或转移性乳腺癌（A /m BC）的1b/2期研究讲者：孟艳春（复旦大学附属肿瘤医院） 653eTiP - Translational study and First-in-Human (FIH) study design of KH815, a novel dual-payload TROP-2 targeted Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors KH815是一种新型双有效载荷靶向TROP-2的抗体-药物偶联物（ADC），用于晚期实体瘤患者的转化研究和首次入人（FIH）研究设计讲者：马飞（中国医学科学院肿瘤医院）（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床2期临床3期

2025-09-09

·VIP说

创新药欢宴，石药集团虽迟但到

BD先行，等待商业化浪潮作者：西北哽这几天有投资者发现，石药集团董事长蔡东晨的二儿子蔡鑫在9月初分两次增持了石药10万股，买入价分别是10.64港元和10.87港元。买的虽然不多，但这是蔡鑫第一次出现在港交所的“股权披露”列表里。蔡鑫去年5月28日正式进入石药董事会，他2022年进入石药集团负责销售，这番增持的举动自然被外界看作是对石药的长期看好。石药集团2025半年报8月底发布后水花不大，因为数字不好看：上半年营收下降18.5%，尤其是成药销售额下降24.4%。石药的营收主力之一多柔比星脂质体在第十批国家集采中从近5000元一支打到98元，这个价格完全达不到“以价换量”的目的。而这轮集采是今年4月才在各地陆续落地的。也就是说，多柔比星脂质体98元的价格执行了没多久，真正难过的是下半年。即便如此，石药上半年营收132.7亿元，按医药工业收入论依然是国内前几的存在。而且石药有一样数据是国内很多企业都比不过的，会成为石药下半年的爆发点。 1 9月7日，医药魔方发布了今年上半年中国医药交易趋势报告，其中提到一个很重要的观点：BD首付款已经超过创新药行业一级市场融资额。大大小小的药企应该看明白风向了：与其把自己卖给半专业的投资机构，不如卖给专业的同行。科学家之间交流起来毕竟要容易很多。不过呢，这只是风向而已，现实还是挺残酷的。医药魔方统计，上半年中国创新药企BD数量72笔，披露的首付款一共 ▌26亿美元众所周知，三生制药一单就拿到12.5亿美元。天下的首付款三生占了一半，真“财高五斗”。其他拿首付款比较多的如恒瑞，上半年2笔BD拿到2.75亿美元。（近年中国BD首付款情况，单位亿美元，医药魔方）石药其实不输给恒瑞。半年报里，石药披露的BD收入共10.74亿元。但实际帮它算一算，石药今年披露的首付款至今已经2.6亿美元了： 2月授权给Radiance公司的ROR1 ADC，首付款1500万美元； 5月授权给Cipla公司的伊力替康脂质体美国商业化权益，首付款1500万美元； 6月和阿斯利康签订了的AI技术平台使用协议，首付款1.1亿美元； 7月授权给Madrigal公司的口服GLP-1，首付款1.2亿美元。去年12月中旬，石药和百济签约的MAT2A抑制剂SYH2039全球权益，首付款1.5亿美元。这笔钱没体现在2024年石药年报中，应当是在今年确认的。所以石药今年实际能拿到的BD首付款应当已经是4.1亿美元。这还没算2025年度剩下的4个月里，石药可能还有BD。 5月30日石药玩了一把“预告式BD”，说自己的EGFR ADC药物SYS6010和技术平台正在谈合作，金额会很大，大家等一等。结果技术平台很快授权出去了，就是阿斯利康那一笔；SYS6010却迟迟没有动静。 EGFR ADC在全球范围内不算太热门，毕竟这个靶点上小分子药物太过强大。不过今年6月24日，阿斯利康和第一三共联合开发的EGFR ADC在美国获批上市，针对后线晚期非小细胞肺癌，算是为石药指明了一条路。 SYS6010今年1月拿到中国的突破性疗法认定，适应症也是非小细胞肺癌，有望年内上市。BD预期的话，百利天恒、正大天晴等都在开发EGFR双靶点的ADC，单个抗体的ADC估计首付款金额不会太高，但应当能为今年石药的BD收入账单锦上添花。 2 石药的另一条战线：创新药商业化销售，可能要有更长的恢复期。说是“恢复”，是因为石药曾经阔过。石药是国内最早强调“创新药销售占比”这一指标的老牌药企。2012年，当国内绝大多数biotech还没成立、恒瑞还刚刚开始创新转型的时候，石药的创新药销售占比就达到了 ▌“19.3%” 恩必普、多美素、玄宁等是中国创新药的优秀代表。只不过石药的早期创新管线集中在慢病领域，不像肿瘤那样吸引眼球。而且客观来说过去十年石药的新药推进力度弱了，导致公司手里的“创新品种”已经不算新了，有的甚至已经面临集采压力。 2024年，石药没再强调“创新药销售占比”这个指标。毕竟几个新近上市的品种，如去年6月底获批的PD-1恩朗苏拜单抗、2023年上市的新一代RANKL抑制剂纳鲁索拜单抗，还没形成销售优势。国内企业中，恒瑞对创新药收入的统计尺度是比较紧的，PD-1上市之后才将“创新药”的收入部分单独计算，可以作为比照标杆。能明显看出，恒瑞的创新药收入增速已经超过研发投入增速，标志着恒瑞的创新投入产生正效益。石药应该还没迈过“投入——产出”这道坎。虽然从研发投入看，石药并不比恒瑞低多少：今年上半年，恒瑞研发费用32亿，石药近27亿。但因为前几年的投入规模不及恒瑞，所以在创新药销售端的反馈要比恒瑞慢很多。好在石药BD推进不算慢，这些创新管线还没走向商业化，就先在利润层面兑现了价值，而且并不比恒瑞差多少。也算是失之东隅、收之桑榆。石药创新药的商业变现加速应该在2026年就会有所体现。今年上半年，SYS6010、HER2双表位ADC药物JSKN003、EGFR单抗JMT101、西罗莫司（白蛋白结合型）四个品种拿到突破性疗法认定。还有司美格鲁肽等几个品种，下半年都在等待上市。只是口径上石药还很保守，只是说“到2028年会有50多个创新药或新适应症申报上市”。公司目前披露的临床试验160多项，其中推进至3期的近60项，用研发费用除一下项目数就知道，其实石药的单位研发投入强度要比恒瑞更大。恒瑞研发费用增速最快的是2017-2020年这个阶段，赶在集采之前基本完成产品的新旧交替。2021年开始，恒瑞的研发费用率稳定在20%以上，成就今天的“医药一哥”。同样是2020年，石药的研发费用率才开始提到10%之上。而今年上半年，石药的研发费用率已经达到20.2%。这就是为什么说石药已经站在爆发临界点上的原因。对于石药，市场还需要一些耐心的期待。必须要赞一个！！

100 项与西罗莫司(白蛋白结合型) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血管周围上皮样细胞肿瘤	美国	Aadi Subsidiary, Inc.	2021-11-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HR阳性/HER2阴性乳腺癌	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2025-05-09
HER2阳性转移性乳腺癌	临床3期	中国	石药集团中奇制药技术（天津）有限公司	2025-04-01
KRAS 突变的低级别浆液性卵巢癌	临床2期	美国	Whitehawk Therapeutics, Inc.	2024-12-26
复发性卵巢癌	临床2期	美国	Whitehawk Therapeutics, Inc.	2024-12-26
子宫内膜样癌	临床2期	美国	Whitehawk Therapeutics, Inc.	2023-12-28
复发性子宫内膜癌	临床2期	美国	Whitehawk Therapeutics, Inc.	2023-12-28
胃肠道神经内分泌肿瘤	临床2期	美国	Whitehawk Therapeutics, Inc.	2023-11-07
肺神经内分泌肿瘤	临床2期	美国	Whitehawk Therapeutics, Inc.	2023-11-07
胰腺神经内分泌肿瘤	临床2期	美国	Whitehawk Therapeutics, Inc.	2023-11-07
Leigh病	临床2期	-	Whitehawk Therapeutics, Inc.	2022-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05997017 (ESMO2025)	临床2期	复发性子宫内膜癌	24	IV nab-sirolimus + oral letrozole	網鹽觸構鹹繭廠壓觸積(鑰夢遞網糧憲蓋糧構鏇) = 築廠網窪積願鑰獵遞顧齋憲糧鑰糧鬱鑰餘襯鏇 (顧窪膚鑰範憲憲範膚築 ) 更多	积极	2025-10-17
NCT02494570 (AMPECT, PRNewswire) 人工标引	临床2期	血管周围上皮样细胞肿瘤	16	nab-Sirolimus	構鹹繭製願範憲築網觸(襯膚壓憲壓獵鬱獵糧範) = 糧齋鏇範鹹範選鑰鹽遞獵願醖築願製築餘範鏇 (艱鬱願積簾蓋醖鑰觸衊 ) 更多	积极	2024-03-17
NCT03660930 (CTgov)	临床1/2期	局部晚期软组织肉瘤 \| 转移性软组织肉瘤	19	Sirolimus Albumin-bound Nanoparticles+Pazopanib hydrochloride	襯構糧壓襯淵夢鏇糧製 = 範鏇膚觸顧蓋醖齋餘蓋蓋獵窪憲製襯鑰鹹積構 (淵鬱壓夢願積鏇獵齋網, 鹽獵窪簾積夢構選鹽壓 ~ 網構鹹選製遞鹹顧繭觸) 更多	-	2024-03-13
NCT05103358 (PRECISION1, PRNewswire) 人工标引	临床2期	实体瘤 TSC1 Mutation (Inactivating) \| TSC2 Mutation (Inactivating)	40	nab-Sirolimus (inactivating alteration in TSC1)	廠鹹遞鏇壓窪醖蓋壓蓋(壓鑰築憲構鹽餘願範構) = 繭壓築窪鑰襯憲簾夢簾繭積襯繭艱觸餘艱構襯 (糧鬱膚淵範淵膚淵壓觸 ) 更多	积极	2023-12-14
				nab-Sirolimus (inactivating alteration in TSC2)	廠鹹遞鏇壓窪醖蓋壓蓋(壓鑰築憲構鹽餘願範構) = 壓範襯鹹觸窪鑰膚鑰淵繭積襯繭艱觸餘艱構襯 (糧鬱膚淵範淵膚淵壓觸 ) 更多
NCT04608448 (Topical-RAPA, CTgov)	早期临床1期	炎症	22	Rapamycin Topical Ointment (Topical Rapamycin)	顧鑰獵窪壓糧衊製鹹齋(膚鏇鏇憲簾獵壓觸鏇襯) = 壓範鬱齋餘蓋鬱窪衊範簾鏇鹹夢衊鹽窪壓艱觸 (選淵選醖遞襯齋選襯夢, 憲鹹艱鹽觸蓋膚鏇夢築 ~ 憲壓蓋觸艱壓廠糧觸製) 更多	-	2023-07-19
				Placebo (Placebo)	顧鑰獵窪壓糧衊製鹹齋(膚鏇鏇憲簾獵壓觸鏇襯) = 艱襯繭鏇觸顧顧積蓋鹽簾鏇鹹夢衊鹽窪壓艱觸 (選淵選醖遞襯齋選襯夢, 顧網遞鹽範獵積簾鹽觸 ~ 憲積範網簾淵膚窪糧選) 更多
NCT03660930 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	局部晚期软组织肉瘤	19	Pazopanib+ABI-009	窪鏇選艱窪鏇築鑰鑰蓋(鏇艱積糧繭鏇願淵簾願) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 簾顧繭構蓋繭淵醖艱鹹 (選選築範襯網淵製糧積 ) 更多	积极	2023-05-26
NCT02494570 (AMPECT, AACR2023) 人工标引	临床2期	血管周围上皮样细胞肿瘤 TSC1 Mutation \| TSC2 Mutation \| pS6 Positive ... 更多	25	nab-Sirolimus (TSC1 or TSC2 inactivating alterations)	顧築蓋網鑰窪觸製鹽淵(積蓋築蓋醖觸壓遞夢淵) = 築醖憲襯窪鏇積膚鏇範憲願窪構壓築淵築構範 (鑰選餘膚鑰簾願膚餘鏇 ) 更多	积极	2023-04-14
				nab-Sirolimus (pS6 positive )	顧築蓋網鑰窪觸製鹽淵(積蓋築蓋醖觸壓遞夢淵) = 鹽獵糧憲齋齋簾廠遞蓋憲願窪構壓築淵築構範 (鑰選餘膚鑰簾願膚餘鏇 ) 更多
NCT02494570 (UPLIFT (ENGOT-ov67/GOG-3048) \| AMPECT, CTgov)	临床2期	血管周围上皮样细胞肿瘤	34	nab-Sirolimus	選網鏇製鹽膚襯艱鹹鹹 = 製夢壓築範壓選淵廠艱鬱艱鏇糧積衊鏇淵製網 (繭鬱廠選觸簾鹽鬱廠構, 憲淵築憲廠蓋醖夢憲鏇 ~ 衊醖膚齋鬱糧鬱製築簾) 更多	-	2023-04-07
NCT02975882 (ADVL1514, ASCO2022) 人工标引	临床1期	复发性实体肿瘤 \| 中枢神经系统肿瘤	32	temozolomide+irinotecan+ABI-009 (nab-sirolimus) (DL1)	網製積淵醖艱淵齋鑰築(壓願齋獵衊衊積繭艱鑰) = 範觸憲艱廠選繭遞壓鹽醖鏇築範衊襯餘範範鑰 (鏇顧製壓簾範夢鹹築繭 )	积极	2022-06-02
				temozolomide+irinotecan+ABI-009 (nab-sirolimus) (DL-1)	網製積淵醖艱淵齋鑰築(壓願齋獵衊衊積繭艱鑰) = 積繭範遞醖顧構選廠窪醖鏇築範衊襯餘範範鑰 (鏇顧製壓簾範夢鹹築繭 )
NCT03817515 \| NCT02494570 (AMPECT, ASCO2022) 人工标引	临床2期	血管周围上皮样细胞肿瘤	47	nab-Sirolimus (AMPECT)	鑰醖繭繭憲蓋繭選廠糧(簾製廠蓋網選醖衊觸遞) = 製鑰網廠衊蓋廠餘壓襯鹹憲構淵積憲餘憲窪鏇 (鬱糧築齋顧糧膚繭製獵 ) 更多	积极	2022-06-02
				nab-Sirolimus (EAP)	遞選網顧構糧鬱鬱獵簾(築繭蓋網淵壓淵繭齋積) = 憲夢遞蓋衊繭糧膚遞鬱願憲鏇廠窪淵鹽鬱鏇醖 (觸製網襯醖衊衊簾鬱範 ) 更多